Gilead names Roche veteran O'Day as CEO
7 drugs that raised eyebrows in Q3
Biosimilars bite into Herceptin in Europe
Πολλαπλή Σκλήρυνση: Επαναστατική θεραπεία «φρενάρει» την εξέλιξη
Roche and Novartis Strengthen Their Presence in the MS Market
Promising rare conditions treatments could upend the market hierarchy
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard to bring their own therapeutics for the disease to market. Multiple sclerosis (MS) is an autoimmune disease that affects the nervous system, and around 2 … Συνεχίστε να διαβάζετε How Biotech is Mastering Multiple Sclerosis: A Review.